


PRODUCT REFERENCE GUIDE







Afrezza® is dispensed in convenient boxes to meet your patients' mealtime insulin needs.¹

See below for a product reference guide, including all Afrezza NDC codes, their contents, and the maximum daily units per box.



COMBINATION BOX OPTIONS

SINGLE BOX OPTIONS

NDC	Afrezza Box Contents	1 Box (30-day supply)	2 Boxes (30-day supply)	3 Boxes (30-day supply)
 NDC 47918-880-18	Afrezza Titration Box [90] 4-unit cartridges [90] 8-unit cartridges Total: 180 cartridges 1080 Afrezza Insulin Units	Total Insulin Units: 1080 Total Cartridges: 180 Max Total Daily Dose: 36 units	Total Insulin Units: 2160 Total Cartridges: 360 Max Total Daily Dose: 72 units	Total Insulin Units: 3240 Total Cartridges: 540 Max Total Daily Dose: 108 units
 NDC 47918-898-18	Afrezza 8 & 12 Unit Combo Box [90] 8-unit cartridges [90] 12-unit cartridges Total: 180 cartridges 1800 Afrezza Insulin Units	Total Insulin Units: 1800 Total Cartridges: 180 Max Total Daily Dose: 60 units	Total Insulin Units: 3600 Total Cartridges: 360 Max Total Daily Dose: 120 units	Total Insulin Units: 5400 Total Cartridges: 540 Max Total Daily Dose: 180 units
 NDC 47918-902-18	Afrezza Titration Box [60] 4-unit cartridges [60] 8-unit cartridges [60] 12-unit cartridges Total: 180 cartridges 1440 Afrezza Insulin Units	Total Insulin Units: 1440 Total Cartridges: 180 Max Total Daily Dose: 48 units	Total Insulin Units: 2880 Total Cartridges: 360 Max Total Daily Dose: 96 units	Total Insulin Units: 4320 Total Cartridges: 540 Max Total Daily Dose: 144 units
 NDC 47918-874-90	Afrezza 4-Unit Cartridges [90] 4-unit cartridges Total: 90 cartridges 360 Afrezza Insulin Units	Total Insulin Units: 360 Total Cartridges: 90 Max Total Daily Dose: 12 units	Total Insulin Units: 720 Total Cartridges: 180 Max Total Daily Dose: 24 units	Total Insulin Units: 1080 Total Cartridges: 270 Max Total Daily Dose: 36 units
 NDC 47918-878-90	Afrezza 8-Unit Cartridges [90] 8-unit cartridges Total: 90 cartridges 720 Afrezza Insulin Units	Total Insulin Units: 720 Total Cartridges: 90 Max Total Daily Dose: 24 units	Total Insulin Units: 1440 Total Cartridges: 180 Max Total Daily Dose: 48 units	Total Insulin Units: 2160 Total Cartridges: 270 Max Total Daily Dose: 72 units
 NDC 47918-891-90	Afrezza 12-Unit Cartridges [90] 12-unit cartridges Total: 90 cartridges 1080 Afrezza Insulin Units	Total Insulin Units: 1080 Total Cartridges: 90 Max Total Daily Dose: 36 units	Total Insulin Units: 2160 Total Cartridges: 180 Max Total Daily Dose: 72 units	Total Insulin Units: 3240 Total Cartridges: 270 Max Total Daily Dose: 108 units

1. Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation.

Important Safety Information

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE

- Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA.
- AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.
- Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

Indications and Usage

- Afrezza (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use

- In patients with type 1 diabetes, must use with a long-acting insulin
- Not recommended for the treatment of diabetic ketoacidosis
- Not recommended in patients who smoke

Contraindications

- During episodes of hypoglycemia
- Chronic lung disease, such as asthma, or chronic obstructive pulmonary disease
- Hypersensitivity to regular human insulin or any of the AFREZZA excipients

Warnings and Precautions

- **Acute Bronchospasm:** Acute bronchospasm has been observed in patients with asthma and COPD. Before initiating, perform spirometry (FEV1) in all patients. Do not use in patients with chronic lung disease.
- **Change in Insulin Regimen:** Carry out under close medical supervision and increase frequency of blood glucose monitoring.
- **Hypoglycemia:** May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairment and hypoglycemia unawareness.
- **Decline in Pulmonary Function:** Assess pulmonary function (e.g., spirometry) before initiating, after 6 months of therapy, and annually, even in the absence of pulmonary symptoms.
- **Lung Cancer:** AFREZZA should not be used in patients with active lung cancer. In patients with a history of lung cancer or at risk for lung cancer, the benefit of AFREZZA use should outweigh this potential risk.
- **Diabetic Ketoacidosis:** More patients using AFREZZA experienced diabetic ketoacidosis in clinical trials. In patients at risk for DKA, monitor and change to alternate route of insulin delivery, if indicated.
- **Hypersensitivity Reactions:** Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA. Discontinue AFREZZA, monitor and treat if indicated.
- **Hypokalemia:** May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
- **Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs):** Observe for signs and symptoms of heart failure; consider TZD dosage reduction or discontinuation if heart failure occurs.

Adverse Reactions

The most common adverse reactions associated with AFREZZA (2% or greater incidence) are hypoglycemia, cough, and throat pain or irritation.

Drug Interactions

Drugs that Affect Glucose Metabolism: Adjustment of insulin dosage may be needed.

Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of hypoglycemia may be reduced or absent.

Full Prescribing Information, including **BOXED WARNING**, is available on www.afrezzahcp.com.